Back to search

University of Crete (UOC)

Διερεύνηση της συσχέτισης των ινσουλινόμορφων αυξητικών παραγόντων και των ενδοθηλινών με την παρουσία μικρομεταστατικών κυττάρων στο αίμα και την πρόγνωση γυναικών με πρώιμο καρκίνο μαστού

Abstract

dc:description

OBJECTIVE: Insulin-like growth factor (IGF)-axis is involved in human oncogenesis and metastasis development for various solid tumors including breast cancer. Aim of this study was to assess the association between IGF-1, IGF-binding protein-3 (IGFBP-3) serum levels and the presence of circulating tumor cells (CTCs) in the peripheral blood of women diagnosed with early breast cancer (EBC), before and after adjuvant chemotherapy.DESIGN:171 patients with early-stage breast adenocarcinomas were retrospectively evaluated. Immunoradiometric (IRMA) assays were employed for the in-vitro determination of IGF-1 and IGFBP-3 serum levels in blood samples collected after surgical treatment and before initiation of adjuvant chemotherapy. CTCs' presence was assessed through detection of cytokeratin-19 (CK-19) mRNA transcripts using quantitative real time reverse transcription polymerase chain reaction (RT-PCR). IGF-1, IGFBP-3 serum levels were correlated with CTCs' presence before and after adjuvant chemotherapy as well as with tumor characteristics including tumor size, axillary lymph node status, oestrogen (ER)/progestorene (PR) and human epidermural growth factor receptor 2 (HER2) receptor status. Log-rank test was applied to investigate possible association between IGF-1, IGFBP-3 serum levels and disease-free interval (DFI) and overall survival (OS).RESULTS:Before initiation of adjuvant therapy IGF-1, IGFBP-3 serum levels were moderately associated (Spearman's rho=0.361, p<0.001) with each other, while presenting significant differences across age groups (all p values<0.05). IGF-1 serum levels did not correlate with the presence of CTCs before initiation (p=0.558) or after completion (p=0.474) of adjuvant chemotherapy. Similarly, IGFBP-3 serum levels did not show significant association with detectable CTCs either before (p=0.487) or after (p=0.134) completion of adjuvant chemotherapy. There was no statistically significant association between the clinical outcome of patients in terms of DFI, OS and IGF-1(DFI: p=0.499; OS: p=0.220) or IGFBP-3 (DFI: p=0.900; OS: p=0.406) serum levels.CONCLUSIONS:IGF-1 and IGFBP-3 serum levels before initiation of adjuvant chemotherapy are not indicative of CTCs' presence in the blood and do not correlate with clinical outcome of women with early-stage breast cancer.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadakis, Georgios
  • Παπαδάκης, Γεώργιος

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • BY_NC_ND
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40609

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadakis, Georgios; Παπαδάκης, Γεώργιος. Διερεύνηση της συσχέτισης των ινσουλινόμορφων αυξητικών παραγόντων και των ενδοθηλινών με την παρουσία μικρομεταστατικών κυττάρων στο αίμα και την πρόγνωση γυναικών με πρώιμο καρκίνο μαστού. University of Crete (UOC), 2017. http://hdl.handle.net/10442/hedi/40609